Wikipedia -WSS

Wikipedia

author：comprehensive 2025-09-30 23:11:09 - browse：627

Stock illustration of computer and medication — Adobe

Digital therapeutics company Click Therapeutics announced Wednesday it will acquire the assets of Better Therapeutics, developer of a software-based treatment for diabetes. Click, which did not disclose how much it is paying for the assets, hopes to adapt Better’s tech for use alongside GLP-1 medications.

Better Therapeutics announced in March that it was delisting from the Nasdaq stock exchange and shutting down operations as it sought strategic alternatives. The company had been, since last year, searching for ways to stay afloat as its cash reserves dwindled.

Last, year, Better received Food and Drug Administration clearance for AspyreRx, a prescription app that delivers cognitive behavioral therapy and had been shown to reduce A1c levels in people with type 2 diabetes. Still, the company has been unable to ramp up significant commercial traction. Better also had a pipeline of other products targeting cardiometabolic conditions, and had made early claims about the benefits of AspyreRx in people taking GLP-1s for diabetes management.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Ionis drug prevents swelling attacks due to hereditary angioedema

hotspot

WSS

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

FDA's Pazdur wants cancer trials to range beyond China alone

Ionis drug prevents swelling attacks due to hereditary angioedema

Gene therapy’s promise and the high cost of hope

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Kidney transplant patients stopped immunosuppressants in trial

explore

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

How one medical school became remarkably diverse

After Sarepta trial failure, Duchenne families brace for more debate

Continuity nursing helped my family in our darkest PICU moments

Prime Medicine says its gene editing passes test in monkeys

Anesthesiologist group: stop taking Ozempic before surgery

Humans aren't the only ones with an imagination. Rats have it too

Affirmative action in medical school literally saved lives

Medicare must police algorithms in Medicare Advantage, Dems say

How one medical school became remarkably diverse

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

entertainment

Shifting the focus from loneliness to social health

Life sciences investors close nearly $6 billion in new funds

Shifting the focus from loneliness to social health

Lung cancer screening guidelines updated for cigarette smokers

Shifting the focus from loneliness to social health

HIV drugs protect against transmission, even in unprotected sex

knowledge

hotspot

knowledge

Wikipedia